Nature Medicine retracts China lung cancer immunotherapy timing paper, citing data integrity concerns — and the fallout could fuel US anti-China sentiment in biopharma.
June 25, 2026 11:11 AM EDT
Retraction of high-profile paper on cancer drug timing could hand ammo to China hawks
Elizabeth Cairns
Senior biopharma journalist
Nature Medicine has retracted a high-profile paper it published in February detailing the results of a China-based trial suggesting that cancer …
Nature Retracts Cancer Study Linking Treatment Timing to Survival
FDA findings lead to medical journal paper retraction | The Jerusalem Post
The U.S.-China biotech crackdown may hurt the scientists America needs the most
HHS, responding to China’s rise, moves to fast-track early drug research
Opinion | 'The Paper's Title Tells You It Shouldn’t be Published': What We Heard This Week
Biosecure didn’t stop China’s rise in biotech. Some lawmakers want to do more
In Depth: U.S.’ Biotech Scrutiny Tests China’s Drugmakers Abroad
NEJM Retracts Pivotal Trial of FDA-Approved Drug
At BIO, tension over China biotech deal regulation looms
Pharmalittle: We're reading about Chinese trial sites being probed, RFK Jr. and peptides, and more
Editors 'no longer have confidence in the integrity of the results'
An Amgen spokesperson said it "takes scientific integrity seriously and respects the role of journals in upholding the peer…
“There is a difference between a policy based on evidence and a broad legislative response that targets China-origin entities as…
PhRMA and BIO mobilize against a wave of anti-China biotech bills in Congress as lawmakers move to curb US dealmaking with China.
The leading drug in biopharma's hottest immunotherapy race reduced the risk of death by 34% in previously untreated Chinese lung…
NEJM retracts pivotal data behind Amgen's Tavneos after FDA probe finds results for 9 patients re-evaluated post-unblinding; EU…
